In order to demonstrate safety, several human studies were performed with AOD9604 (supplementary data): 1). METAOD001: A Phase I (double-blind, placebo-controlled, dose escalation) safety study with doses (ranging from 25 to 400 µg/kg AOD9604) administered intravenously to 15 healthy adult male volunteers presenting with a BMI between 24 and 30 kg/m2. A single dose of recombinant hGH (0.12 international units/kg) was administered intravenously as positive control. 2). METAOD002: A Phase IIa (double-blind, placebo-controlled 4 × 4 Latin Square design) safety study with single doses (25, 50 and 100 µg/kg AOD9604) administered intravenously to 23 healthy clinically obese males presenting with a BMI ≥ 35 kg/m2. 3). METAOD003: A Phase IIa (double-blind, placebo-controlled 4 × 4 Latin Square design) safety study with single doses (9, 27 and 54 mg AOD9604) administered orally (capsules) to 17 healthy, clinically obese males presenting with a BMI ≥ 35 kg/m2. 4). METAOD004: A Phase IIa (double-blind, placebo-controlled, dose escalation) safety study with multiple daily doses (9, 27 or 54 mg AOD9604) administered orally (capsules) for seven days in 36 healthy clinically obese males presenting with a BMI ≥ 30 kg/m2. 5). METAOD005: A Phase IIb (randomized, double-blind, placebo-controlled) study to assess the efficacy (reduction in body weight), safety and tolerability of 12 weeks treatment with daily doses (1, 5, 10, 20 or 30 mg AOD9604) administered orally (capsules) in 300 healthy, clinically obese males, and females of non-child bearing potential, with a BMI ≥ 35 kg/m2. 6). METAOD006: A Phase IIb, randomized, double-blind, placebo-controlled study to assess the efficacy (reduction in body weight), safety and tolerability of 24 weeks treatment with different doses of AOD9604 tablets (0.25 mg, 0.5 mg, 1 mg, or placebo) in 502 obese adults.
The evidence so far suggests that there may be some effect on cartilage and bone densities, and it is correlated with weight loss. I understand that there is no evidence to suggest that it stimulates the release of IGF-1, which is the mechanism via which growth hormone gets most of its purported performance enhancing effects (i.e. muscle bulk). Whilst this is a decent list of things to test if one is considering AOD9604 as simply a variant of growth hormone, it is by no means exhaustive of all the mechanisms via which a drug can enhance athletic performance. The evidence thus far suggests that AOD9604 could be performance enhancing, but there is nothing I would hang my hat on. That is why I maintain that Dank is more sorcerer than scientist.
AOD9604 is a peptide fragment (hGH Fragment 177-191) of the C-terminus of Human Growth Hormone to which a tyrosine is added at the N-terminal end.  Studies have suggested that AOD9604 is more effective than its predecessor AOD9401 in its ability to stimulate lipolytic (fat burning) and anti-lipogenic activity. Like Growth Hormone, AOD9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis (prevents the transformation of  fatty food materials into body fat) both in laboratory testing and in animals and humans.  Recent  clinical research studies have shown that  AOD9604 did show a reduction of body fat in the mid abdominal area in both obese, over-weight, and average built people.
I have questions about combined therapy of CJC 1295 and Ipamorelin at the same time on a daily basis for both. The compounding pharmacies do not clearly state whether the CJC is with or without DAC. If it is the CJC with DAC, which sustains elevated GH and IGF-1 for several days, would taking it nightly in conjunction with the Ipramorelin, that is suggested to be taken TID but is being recommended only once at night, be over-stimulatory? If the CJC is without DAC, why take two pepetides simultaneously ,that have similar effects? I am just not clear why taking a daily dose of CJC with Ipamorelin as a single dose is better than taking the CJC with DAC twice per week alone or take the CJC with DAC for a while then switch to the Ipamorelin for a while?
A comparison of β3-AR RT-PCR expression levels in white (A) and brown (B) adipose tissues from lean and obese mice treated for 14 d with saline, AOD9604, or hGH. Results are displayed as a percentage, compared with lean controls, and expressed as the mean ± SE of three determinations in each group. *, P < 0.05; #, P< 0.05 obese control vs. lean control.
We then wanted to determine the importance of theβ 3-AR in mediating both the chronic and acute effects of AOD9604 or hGH using β3-KO mice. Theβ 3-KO mice and the control WT strain were given either AOD9604 or hGH for 28 d at the concentrations used in the previous study. As shown in Fig. 4A, both AOD9604 and hGH increased body weight after 28 d in lean WT mice similar to the effect seen after 14 d in lean C57BL/6J mice (Fig. 1A). This effect was not observed in the β3- KO mice (Fig. 4B) in whom AOD9604 or hGH had no significant effect on body weight.
Following amplification, PCR products were electrophoresed on 1.3% agarose gels and transferred onto Hybond N+ membranes (RPN 303B, Amersham Pharmacia Biotech) by Southern blotting in 0.4 M NaOH/1 M NaCl. The membranes were rinsed for 5 min in 0.5 M Tris-HCl (pH 7.5)/1 M NaCl and then in 0.3 M NaCl/30 mM sodium citrate, and air dried. Membranes were apposed directly to a phosphor imager screen for 18 h, and scanned using a Storm PhosphorImager and data quantitated using MCID software (Imaging Research, Inc., St. Catherines, Ontario, Canada). The β3-AR product bands were normalized against the β-actin control, averaged, and RNA isolated from treated animals was expressed against control animals.
Just as you could eat more calories than you think if you aren’t keeping track, you might miss some positive results of your efforts if you aren’t tracking your progress. Weigh yourself weekly. Take body measurements of your waist, legs, chest, and arms every other week. Measure your body fat percentage. Take photos of yourself once a month. Sometimes the scale won’t show results from week to week, but if you have all of the other methods of tracking in place, you’ll be able to see your efforts are being rewarded.
As a general rule, regardless of your goal, if you are just looking to take one product, with the least amount of fuss and injections as possible, then it should be CJC-1295 DAC at 2mg (1 vial) per week. Due to its long half-life it causes your overall level of GH (Growth Hormone) to rise, and you will therefore see some improvements in things which go along with having higher levels of GH and IGF-1 such as improved body shape, sleep, skin and general wellbeing (although it can make you tired for the first 1-2 weeks while the body adjusts). Your dosage can be taken as just one injection per week (note that you may notice a head rush/flushing for 15-20 minutes after your injection due to the release of GABA in the body, a sign the product is working).
In June 2007, the NDPSC decided to extend the exemption from the limit on paracetamol combinations being allowed as general sale products to include phenylephrine (as long as it also qualified as exempt from scheduling through the phenylephrine entries). At that time, the NDPSC considered that the safety profile of these substances was such that allowing a fixed combination to be unscheduled was reasonable.

The Ketogenic Diet is designed to force your body into ketosis, which is a normal metabolic state. Typically, the body burns carbohydrates from food to function, but when you adopt a diet of low calories (and low carbohydrates) your body switches into ketosis. When your body is in a state of ketosis the body is burning fat for energy, meaning you are tapping into the body’s fat storage that is often the hardest to shift.
The biggest negative, and this is a big one, is that AOD9604 has undergone very rigorous scientific testing, and has been found to have no effect in humans (3). When AOD9604 was first developed, it showed significant promise as a weight loss treatment. A special strain of obese mice supplemented with the peptide showed a reduction in weight, increased fat oxidation, and raised plasma glycerol, which are indicators of lipolysis, or fat burning (5). Subsequent studies in obese mice and rats attempted to show that the peptide works to burn fat in the same way as human growth hormone, but found that this was not the case, meaning that the fact this peptide resembled hGH was meaningless. Scientists were unable to determine how this peptide was working in mice (6).
In June 2007, the NDPSC decided to extend the exemption from the limit on paracetamol combinations being allowed as general sale products to include phenylephrine (as long as it also qualified as exempt from scheduling through the phenylephrine entries). At that time, the NDPSC considered that the safety profile of these substances was such that allowing a fixed combination to be unscheduled was reasonable.
AOD9604 is promoted heavily by various manufacturers as a substance that is able to burn fat and assist in the repair of muscle and cartilage. The fact that this product derives from, and claims to mimic the effects of a powerfully anabolic banned substance provides a psychological incentive to many potential users, as does the attention drawn by the AFL "peptides" scandal of early 2013 and the subsequent report by the Australian Crime Commission (1).
Because these peptides are so numerous and variable in structure, their effects are likewise varied and wide-ranging. One class of these peptides are known as growth hormone secretagogues, and cause the secretion of one’s own, natural hGH in the body. These peptides have been shown to be very useful in the treatment of age-related conditions, osteoporosis, obesity, and various chronic inflammatory diseases, and have several advantages over traditional hGH administration.

The male β3-KO mice and wild-type (WT) that were used in this study were offspring of animals provided by Dr. Bradford Howell (Beth Israel Hospital, Harvard Medical School, Boston, MA). The animals were bred and housed in the central animal house facility (Monash University). For chronic studies, animals were housed in the Departmental Animal Facility (Biochemistry, Monash University). For acute energy expenditure studies, animals were transported to the Department of Medicine (University of Melbourne), acclimatized, and killed following experimentation. The WT andβ 3-KO mice genotype were verified by breeding records and RT-PCR analysis performed in the laboratory of Professor Roger Summers.


In summary, we found that weight loss in obese individuals undergoing gastric bypass surgery is associated with higher natriuretic peptide concentrations across a range of loading conditions. This observation is consistent with a higher “set point” of natriuretic peptide levels after weight loss. That these findings are accompanied by improvements in blood pressure, heart rate and echocardiographic diastolic function provides persuasive evidence that the increase in natriuretic peptides with weight loss is “primary” and not secondary to alterations in cardiac structure or function.
Paracetamol/caffeine formulations have a long-established safety and efficacy profile over 25 years of use as an open-sale medicine in major markets around the world. The paracetamol/caffeine combination analgesic was registered as a schedule 2 product in Australia and has been marketed since 2010. Since that time no new significant issues or potential risks have been reported.

This is cutting edge science and i freely admit is a PE...you could argue whey, bcaa or even intermittent fasting does the same thing, just not as refined hence the argument and confusion is that the substance is grey because the peptide stimulates natural GH which not even wada or asada know how to pidgeon hole it....its mostly unclassified...this is why we will be just fine... are you starting to see the glaring holes in your facts yet?
Ultimately, it needs to be trialled in athletes. But that would never happen. As a substance with no therapeutic use, there is no need to ever test it to determine its effect on athletic performance. You don't need the same standard of evidence for drugs like EPO (synthetic replicas of hormones), where the primary biological effect studied in clinical trials of non-athletes is clearly and blatantly performance enhancing. With something like AOD9604, the waters are much murkier with respect to athletic performance.
Conclusions: Subcutaneous administration of CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 ug/ kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC 1295 as a therapeutic agent.
OxySelect Pink is an advanced thermogenic and is the only diet pill specifically formulated to enhance the curves of a woman’s body. While other products contain stimulants and huge quantities of dubious fillers and preservatives, OxySelect Pink uses clinically-tested, all-natural extracts designed to help you lose weight. OxySelect Pink is one of the best choices for women looking to get leaner.

Australians can buy peptides online legally here in Australia. Due to recent changes in regulations surrounding the promotion and sale of peptide hormones, we are not legally allowed to offer our peptide products for sale to the general public without first qualifying each potential patient. The process is simple and provided there is nothing within your medical history indicating peptide treatment would be detrimental, please feel free to register to purchase peptides. Fill in the online medical evaluation and our highly qualified hormone specialists will assist you in obtaining the best peptide supplement to meet your goals.
×